Skip to content

Trial · Interventional

TerminatedPhase 2Results postedRegistry data

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Overview

Status
Terminated
Phase
Phase 2
Enrollment
28 participants (actual)
Sponsor
Stealth BioTherapeutics Inc. · Industry
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

United States

Start
Dec 2016
Primary completion
9 Mar 2020
Completion
9 Apr 2020
First posted
29 Nov 2016 (estimated)
Last update posted
17 Dec 2021
Conditions
Primary Mitochondrial Disease

Timeline

1 trial · 1 stopped early · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201620172018201920202021
  1. Ph 2

    Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

    NCT02976038

    Dec 2016 to 9 Apr 2020

    Terminated

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial

Interventions

  • elamipretideDrug

Arms1

  • Experimental

    elamipretide

    Open-label once daily subcutaneous injection of 40mg elamipretide

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Distance Walked on Six Minute Walk Test

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit

Secondary outcomes(11)
  1. EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    EuroQol 5 dimensions 5 levels (EQ-5D-5L) by visit. Count of participants per arm, or severity level of dimension. Measures 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Score ranges from 5-25 with lower score=better outcome, and higher score means a worse outcome.

  2. Euroquol Visual Analog Scale

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Euroquol Visual Analog Scale (EQ VAS): A patient-reported measure. The visual scale is numbered from 0 to 100, participants are directed as follows: "100 means the best health you can imagine, 0 means the worst health you can imagine. Mark an X on the scale to indicate how your health is TODAY." Higher scores mean better outcome, lower scores mean worse outcome.

  3. NeuroQOL Fatigue Questionnaire

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Change from baseline in NeuroQOL Fatigue Questionnaire by visit. Questionnaire is comprised of 8 questions measuring participants incidence of fatigue affecting activities of daily living. Participants respond by choosing one of the following: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always, with a lower score meaning a better outcome with fatigue affecting participant less, and high score meaning a worse outcome, with fatigue affecting the participant more. Total raw scores range from 8-40. Scores were converted to percentages: range0-100%. Change from baseline score: negative number means improved from baseline, positive number means worsened compared to baseline.

  4. Patient Global Assessment : Categorical

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Patient Global Assessment \[PGA\] Score by Visit, count of participants. Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.

  5. Patient Global Assessment: Continuous Variable

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Patient Global Assessment \[PGA\] Score by Visit, Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, lower score means worse outcome.

  6. Work Limitations Questionnaire

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Work Limitations Questionnaire by visit. Comprised of 25 items, in 4 categories, or demands: Mental/Interpersonal, Output Tasks, Physical Tasks, and Time Management, measuring the degree to which employed individuals are experiencing limitations on-the-job due to their health problems, and health-related productivity loss. 1= All of the time (100%), 2= most of the time, 3=some of the time (about 50%), 4=slight bit of time, 5=none of the time (0%), 6=does not apply to my job. (Presenteeism). The WLQ items ask respondents to rate their level of difficulty or ability to perform specific job demands. Scale score range from 0 (limited none of the time=better outcome) to 100 (limited all of the time= worse outcome) and represent the reported amount of time in the prior two weeks respondents were limited on-the-job.

  7. Physician Global Assessment Score (PhGA) by Visit

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Physician Global Assessment- Mean Score by visit. PGA Scale asks physician to rate participant's current health status as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means lower health status, worse outcome; lower score means better health status, better outcome.

  8. Physician Global Assessment (PhGA): Categorical

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Physician Global Assessment \[PhGA\] Score by Visit, Physician-reported current health status by visit. PhGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.

  9. PMMSA Individual Items

    Time frame · Baseline, Week 13, 26, 52, 104, 156, End of Study (Week 160)

    Registry description

    The PMMSA is a patient-reported outcome measure, assessing a participant's "worst feeling" of 10 symptoms during the last 24 hours: tiredness at rest, tiredness during activities, muscle weakness at rest, muscle weakness during activities, balance, vision, abdominal discomfort, muscle pain, numbness, and headache using a 4-point scale: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Max Score =40= worse outcome, Min score= 10= better outcome on scale. PMMSA Individual Items shows number or participants with mild, moderate, severe or no symptoms at all.

  10. Total Fatigue Score_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Change from baseline in the Total Fatigue score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 4 symptoms: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q1 to Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.

  11. Total Fatigue Score During Activities_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

    Time frame · Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

    Registry description

    Change from baseline in the Total Fatigue during Activities score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 2 symptoms: Tiredness during activities, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q2 and Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 2-8; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

Distance Walked on Six Minute Walk Test

GroupValue (meters)Spread
Elamipretide3.652.68
Secondary and other outcome results(7)
Secondary outcomeCount of participants· Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)

GroupValue (Participants)
No Problem12
Slight Problem8
Moderate Problem4
Severe Problem3
Extreme Problem1
Secondary outcomeMean· Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

Euroquol Visual Analog Scale

GroupValue (score on a scale)Spread
Elamipretide65.2917.83
Secondary outcomeMean· Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

NeuroQOL Fatigue Questionnaire

GroupValue (score on a scale)Spread
Elamipretide-8.3916.43
Secondary outcomeCount of participants· Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

Patient Global Assessment : Categorical

GroupValue (Participants)
Elamipretide1
Secondary outcomeMean· Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

Patient Global Assessment: Continuous Variable

GroupValue (score on a scale)Spread
Elamipretide3.610.99
Secondary outcomeMean· Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

Work Limitations Questionnaire

GroupValue (score on a scale)Spread
Elamipretide67.5915.58
Secondary outcomeMean· Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

Physician Global Assessment Score (PhGA) by Visit

GroupValue (score on a scale)Spread
Elamipretide3.320.61

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
ElamipretideOpen-label once daily subcutaneous injection of 40mg elamipretide elamipretide: 40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.0 / 288 / 2828 / 28

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 16 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Investigator determines the subject can, and subject agrees to, adhere to the trial requirements for the length of the trial including self-administration (by subject or trained caregiver) of the study drug * Subject completed the End-of-Study Visit in SPIMM-202 Exclusion Criteria: * Subject has any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all trial requirements * Subject has received any investigational compound (excluding elamipretide) and/or has participated in another interventional clinical trial within 30 days prior to the SPIMM-203 Baseline Visit (excluding SPIMM-202) or is concurrently enrolled in any non-interventional research of any type judged to be scientifically or medically incompatible with the trial as deemed by the Investigator in consultation with the Sponsor * Subject experienced an adverse reaction attributed to study drug resulting in permanent discontinuation of study drug in the SPIMM-202 trial. * Female subjects who are pregnant, planning to become pregnant, or lactating * Subject has undergone an in-patient hospitalization within the 1 month prior to the SPIMM-203 Baseline Visit

PepBank is a research reference. Talk to a doctor before you use any peptide.